Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2023-06-23 Regulatory Filings
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings
2023-06-23 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by TG Therapeutics, Inc. It reports the submission of matters to a vote of security holders at the company's 2023 Annual Meeting held on June 14, 2023. The document details the voting results for various proposals including election of directors, ratification of auditors, executive compensation advisory vote, and amendment to the certificate of incorporation. The key content is the official results from shareholder votes at the annual meeting. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document is about voting results, not the proxy solicitation materials or the annual report itself. Therefore, the correct classification is DVA with high confidence.
2023-06-15 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-06-06 English
Regulatory Filings 2023
Regulatory Filings
2023-06-02 English
10-Q
Interim / Quarterly Report Q1 2023
2023-05-08 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is identified as a Schedule 14A filing, which is a Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is labeled as 'Definitive Additional Materials' related to the proxy statement. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The document length is short (1077 characters), consistent with additional proxy materials rather than a full report. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI).
2023-05-01 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.